Higher Ropeginterferon Alfa-2b Dose Regimen Demonstrates Long-Term Benefits in Polycythemia Vera
“Our results suggest that a higher initiating-dose regimen, with the flexibility of dose schedule adjustment from biweekly to monthly, i.e., once every 3-5 weeks, after the CHR is stabilized with 1 year of ropeg treatment is associated with a high chance of neoplastic cell clearance and robust clinical
“Our results suggest that a higher initiating-dose regimen, with the flexibility of dose schedule adjustment from biweekly to monthly, i.e., once every 3-5 weeks, after the CHR is stabilized with 1 year of ropeg treatment is associated with a high chance of neoplastic cell clearance and robust clinical